Spyre Therapeutics, Inc.
SYRE
$75.40
$0.360.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 60.41M | 44.64M | 45.25M | 40.15M | 41.62M |
| Gross Profit | -60.41M | -44.64M | -45.25M | -40.15M | -41.62M |
| SG&A Expenses | 15.23M | 12.53M | 11.64M | 11.79M | 11.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.64M | 57.17M | 56.89M | 51.94M | 53.57M |
| Operating Income | -75.64M | -57.17M | -56.89M | -51.94M | -53.57M |
| Income Before Tax | -69.01M | -62.53M | -11.18M | -36.72M | -44.79M |
| Income Tax Expenses | -- | 0.00 | -- | -- | -15.00K |
| Earnings from Continuing Operations | -69.01M | -62.53M | -11.18M | -36.72M | -44.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.01M | -62.53M | -11.18M | -36.72M | -44.77M |
| EBIT | -75.64M | -57.17M | -56.89M | -51.94M | -53.57M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.74 | -0.69 | -0.15 | -0.49 | -0.60 |
| Normalized Basic EPS | -0.79 | -0.52 | -0.12 | -0.48 | -0.46 |
| EPS Diluted | -0.74 | -0.69 | -0.15 | -0.49 | -0.60 |
| Normalized Diluted EPS | -0.79 | -0.52 | -0.12 | -0.48 | -0.46 |
| Average Basic Shares Outstanding | 78.55M | 75.09M | 60.41M | 60.33M | 60.27M |
| Average Diluted Shares Outstanding | 78.55M | 75.09M | 60.41M | 60.33M | 60.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |